These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28286802)

  • 21. The Antibiotic Efflux Protein TolC Is a Highly Evolvable Target under Colicin E1 or TLS Phage Selection.
    Tamer YT; Gaszek I; Rodrigues M; Coskun FS; Farid M; Koh AY; Russ W; Toprak E
    Mol Biol Evol; 2021 Sep; 38(10):4493-4504. PubMed ID: 34175926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental Evolution of the TolC-Receptor Phage U136B Functionally Identifies a Tail Fiber Protein Involved in Adsorption through Strong Parallel Adaptation.
    Burmeister AR; Tzintzun-Tapia E; Roush C; Mangal I; Barahman R; Bjornson RD; Turner PE
    Appl Environ Microbiol; 2023 Jun; 89(6):e0007923. PubMed ID: 37191555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophage therapy for drug-resistant
    Liu K; Wang C; Zhou X; Guo X; Yang Y; Liu W; Zhao R; Song H
    Front Cell Infect Microbiol; 2024; 14():1336821. PubMed ID: 38357445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "French Phage Network" Annual Conference-Seventh Meeting Report.
    Schiettekatte O; Beurrier E; De Sordi L; Chevallereau A
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations.
    Morrisette T; Kebriaei R; Lev KL; Morales S; Rybak MJ
    Pharmacotherapy; 2020 Feb; 40(2):153-168. PubMed ID: 31872889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
    Knoll BM; Mylonakis E
    Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacteriophages: an appraisal of their role in the treatment of bacterial infections.
    Hanlon GW
    Int J Antimicrob Agents; 2007 Aug; 30(2):118-28. PubMed ID: 17566713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Creature features: The lively narratives of bacteriophages in Soviet biology and medicine.
    Myelnikov D
    Notes Rec R Soc Lond; 2020 Dec; 74(4):579-597. PubMed ID: 33177748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2004 ASM Conference on the New Phage Biology: the 'Phage Summit'.
    Adhya S; Black L; Friedman D; Hatfull G; Kreuzer K; Merril C; Oppenheim A; Rohwer F; Young R
    Mol Microbiol; 2005 Mar; 55(5):1300-14. PubMed ID: 15720541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the potential of phage and their applications.
    Khambhati K; Bhattacharjee G; Gohil N; Maurya R; Singh V
    Prog Mol Biol Transl Sci; 2023; 200():1-12. PubMed ID: 37739550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
    Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
    Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phage and phage cocktails formulations.
    Mani I
    Prog Mol Biol Transl Sci; 2023; 200():159-169. PubMed ID: 37739554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
    Rossitto M; Fiscarelli EV; Rosati P
    Front Microbiol; 2018; 9():775. PubMed ID: 29780361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.
    Łusiak-Szelachowska M; Międzybrodzki R; Drulis-Kawa Z; Cater K; Knežević P; Winogradow C; Amaro K; Jończyk-Matysiak E; Weber-Dąbrowska B; Rękas J; Górski A
    J Biomed Sci; 2022 Mar; 29(1):23. PubMed ID: 35354477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii.
    Mukhopadhyay S; Zhang P; To KKW; Liu Y; Bai C; Leung SSY
    Int J Antimicrob Agents; 2023 Nov; 62(5):106951. PubMed ID: 37574030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phage therapy: a reappraisal of bacteriophages as antibiotics.
    Inal JM
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):237-44. PubMed ID: 12956433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phage therapy: awakening a sleeping giant.
    Roach DR; Debarbieux L
    Emerg Top Life Sci; 2017 Apr; 1(1):93-103. PubMed ID: 33525818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacteriophage therapy.
    Summers WC
    Annu Rev Microbiol; 2001; 55():437-51. PubMed ID: 11544363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.